Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Caribou Biosciences, Inc.CRBU · Entity 6445 | Chief Business Officer | February 20, 2026 | February 25, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Caribou Biosciences, Inc.
Report date February 20, 2026 · Filed February 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 104,998 |
Ending reported balance
After 2026-02-24 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-02-20 · Grant · Acquired 45,000 · Balance 111,936 F1: This reflects restricted stock units ("RSUs") that vest in four equal annual installments beginning on February 20, 2027, subject to the reporting person continuing to provide service to the Issuer through the applicable vesting dates. The RSUs will be settled in stock within 30 days after each vesting date. Row 2 · 2026-02-24 · Sale · Disposed 6,938 · Balance 104,998 F2: Reflects the number of shares of common stock that were sold in a "sell-to-cover" transaction for the sole purpose of satisfying tax withholding obligations in connection with the vesting of RSUs previously granted to the reporting person and does not represent a discretionary trade by the reporting person. This transaction was made pursuant to a Rule 10b5-1 trading plan in the form of a durable sell-to-cover instruction adopted prior to the 2023 amendments to Rule 10b5-1. The trading plan provides for the automatic sale of shares of common stock necessary to satisfy the reporting person's tax withholding obligations incurred in connection with the vesting of RSUs. |
| Option to purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $1.80 · Expires 2036-02-19 | Direct | 202,500 |
Reported balance
After 2026-02-20 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-02-20 · Grant · Acquired 202,500 · Balance 202,500 F3: 1/48 of the total number of shares subject to this option will vest on each monthly anniversary of the grant date such that the option will be fully vested on February 20, 2030, subject to the reporting person continuing to provide service to the Issuer through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This reflects restricted stock units ("RSUs") that vest in four equal annual installments beginning on February 20, 2027, subject to the reporting person continuing to provide service to the Issuer through the applicable vesting dates. The RSUs will be settled in stock within 30 days after each vesting date.
F2: Reflects the number of shares of common stock that were sold in a "sell-to-cover" transaction for the sole purpose of satisfying tax withholding obligations in connection with the vesting of RSUs previously granted to the reporting person and does not represent a discretionary trade by the reporting person. This transaction was made pursuant to a Rule 10b5-1 trading plan in the form of a durable sell-to-cover instruction adopted prior to the 2023 amendments to Rule 10b5-1. The trading plan provides for the automatic sale of shares of common stock necessary to satisfy the reporting person's tax withholding obligations incurred in connection with the vesting of RSUs.
F3: 1/48 of the total number of shares subject to this option will vest on each monthly anniversary of the grant date such that the option will be fully vested on February 20, 2030, subject to the reporting person continuing to provide service to the Issuer through each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 24, 2026 Filed Feb 25, 2026 01:54 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | SaleCommon Stock | 6,938 | $1.96 | $13,598.48 |
DisclosureSEC source: 0001891113-26-000002 · wk-form4_1771984441.xml · nonDerivative · entry 2 Khan Ruhi Ahmad · CIK 0001891113 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 104,998 F2 · kind: Reflects the number of shares of common stock that were sold in a "sell-to-cover" transaction for the sole purpose of satisfying tax withholding obligations in connection with the vesting of RSUs previously granted to the reporting person and does not represent a discretionary trade by the reporting person. This transaction was made pursuant to a Rule 10b5-1 trading plan in the form of a durable sell-to-cover instruction adopted prior to the 2023 amendments to Rule 10b5-1. The trading plan provides for the automatic sale of shares of common stock necessary to satisfy the reporting person's tax withholding obligations incurred in connection with the vesting of RSUs. F2 · shares: Reflects the number of shares of common stock that were sold in a "sell-to-cover" transaction for the sole purpose of satisfying tax withholding obligations in connection with the vesting of RSUs previously granted to the reporting person and does not represent a discretionary trade by the reporting person. This transaction was made pursuant to a Rule 10b5-1 trading plan in the form of a durable sell-to-cover instruction adopted prior to the 2023 amendments to Rule 10b5-1. The trading plan provides for the automatic sale of shares of common stock necessary to satisfy the reporting person's tax withholding obligations incurred in connection with the vesting of RSUs. Read SEC document |
| February 20, 2026 Filed Feb 25, 2026 01:54 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | GrantOption to purchase Common Stock · Derivative | 202,500 | $0.00 Strike: $1.80 | $0.00 |
DisclosureSEC source: 0001891113-26-000002 · wk-form4_1771984441.xml · derivative · entry 3 Khan Ruhi Ahmad · CIK 0001891113 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 202,500 Underlying: Common Stock · 202,500 shares Expires 2036-02-19 F3 · derivative.exercise_date: 1/48 of the total number of shares subject to this option will vest on each monthly anniversary of the grant date such that the option will be fully vested on February 20, 2030, subject to the reporting person continuing to provide service to the Issuer through each such vesting date. Read SEC document |
| February 20, 2026 Filed Feb 25, 2026 01:54 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | GrantCommon Stock | 45,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001891113-26-000002 · wk-form4_1771984441.xml · nonDerivative · entry 1 Khan Ruhi Ahmad · CIK 0001891113 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 111,936 F1 · shares: This reflects restricted stock units ("RSUs") that vest in four equal annual installments beginning on February 20, 2027, subject to the reporting person continuing to provide service to the Issuer through the applicable vesting dates. The RSUs will be settled in stock within 30 days after each vesting date. Read SEC document |
| February 21, 2025 Filed Feb 22, 2025 01:19 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | SaleCommon Stock | 3,564 | $1.35 | $4,811.40 |
DisclosureSEC source: 0001891113-25-000003 · wk-form4_1740187160.xml · nonDerivative · entry 2 Khan Ruhi Ahmad · CIK 0001891113 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,936 F2 · kind: Reflects the number of shares of common stock that were sold in a "sell to cover" transaction for the sole purpose of satisfying tax withholding obligations in connection with the vesting of RSUs previously granted to the reporting person and does not represent a discretionary trade by the reporting person. This transaction was made pursuant to a Rule 10b5-1 trading plan in the form of a durable sell-to-cover instruction adopted prior to the 2023 amendments to Rule 10b5-1. The trading plan provides for the automatic sale of shares of common stock necessary to satisfy the reporting person's tax withholding obligations incurred in connection with the vesting of RSUs. F2 · shares: Reflects the number of shares of common stock that were sold in a "sell to cover" transaction for the sole purpose of satisfying tax withholding obligations in connection with the vesting of RSUs previously granted to the reporting person and does not represent a discretionary trade by the reporting person. This transaction was made pursuant to a Rule 10b5-1 trading plan in the form of a durable sell-to-cover instruction adopted prior to the 2023 amendments to Rule 10b5-1. The trading plan provides for the automatic sale of shares of common stock necessary to satisfy the reporting person's tax withholding obligations incurred in connection with the vesting of RSUs. F3 · price: This transaction was executed in multiple trades on 2/21/2025 at prices ranging from $1.32 to $1.35. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the specified range. Read SEC document |
| February 20, 2025 Filed Feb 22, 2025 01:19 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | GrantOption to purchase Common Stock · Derivative | 170,000 | $0.00 Strike: $1.41 | $0.00 |
DisclosureSEC source: 0001891113-25-000003 · wk-form4_1740187160.xml · derivative · entry 3 Khan Ruhi Ahmad · CIK 0001891113 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 170,000 Underlying: Common Stock · 170,000 shares Expires 2035-02-19 F4 · derivative.exercise_date: 25% of the options will vest upon the one-year anniversary of the grant date, February 20, 2026, and 1/48th will vest monthly thereafter over the 36-month period following the one-year cliff, subject to the reporting person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| February 20, 2025 Filed Feb 22, 2025 01:19 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | GrantCommon Stock | 37,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001891113-25-000003 · wk-form4_1740187160.xml · nonDerivative · entry 1 Khan Ruhi Ahmad · CIK 0001891113 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,500 F1 · shares: This reflects restricted stock units ("RSUs") that vest in four equal annual installments beginning on February 20, 2026, subject to the reporting person's continued services to the Issuer through the applicable vesting dates. The RSUs will be settled in stock within 30 days after each vesting date. Read SEC document |
| February 20, 2024 Filed Feb 22, 2024 22:21 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | GrantOption to purchase Common Stock · Derivative | 153,000 | $0.00 Strike: $6.81 | $0.00 |
DisclosureSEC source: 0001628280-24-006425 · wk-form4_1708640476.xml · derivative · entry 2 Khan Ruhi Ahmad · CIK 0001891113 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 153,000 Underlying: Common Stock · 153,000 shares Expires 2034-02-19 F2 · derivative.exercise_date: 25% of the options will vest upon the one-year anniversary of the grant date, February 20, 2025, and 1/48th will vest monthly thereafter over the 36-month period following the one-year cliff, subject to the reporting person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| February 20, 2024 Filed Feb 22, 2024 22:21 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | GrantCommon Stock | 33,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-006425 · wk-form4_1708640476.xml · nonDerivative · entry 1 Khan Ruhi Ahmad · CIK 0001891113 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,000 F1 · shares: This reflects restricted stock units ("RSUs") that vest in four equal annual installments beginning on February 20, 2025, subject to the reporting person's continued services to the Issuer through the applicable vesting dates. The RSUs will be settled in stock within 30 days after each vesting date. Read SEC document |
| February 21, 2023 Filed Feb 23, 2023 22:12 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | GrantOption to purchase Common Stock · Derivative | 131,000 | $0.00 Strike: $6.12 | $0.00 |
DisclosureSEC source: 0001619856-23-000025 · wf-form4_167719032608820.xml · derivative · entry 1 Khan Ruhi Ahmad · CIK 0001891113 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,000 Underlying: Common Stock · 131,000 shares Expires 2033-02-20 F1 · derivative.exercise_date: The shares subject to this option will vest in equal monthly installments starting on the first monthly anniversary of the grant date until the option is fully vested on February 21, 2027, subject to the reporting person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| August 22, 2022 Filed Aug 24, 2022 21:29 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | GrantOption to purchase Common Stock · Derivative | 70,000 | $0.00 Strike: $9.90 | $0.00 |
DisclosureSEC source: 0001209191-22-047370 · doc4.xml · derivative · entry 1 Khan Ruhi Ahmad · CIK 0001891113 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2032-08-21 F1 · derivative.exercise_date: 1/48th of the shares subject to this option will vest on September 22, 2022, and on the corresponding day of each month thereafter, subject to the reporting person's continued services to the Issuer through the applicable vesting dates. Read SEC document |
| November 15, 2021 Filed Nov 16, 2021 23:58 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | GrantOption to purchase Common Stock · Derivative | 225,000 | $0.00 Strike: $21.73 | $0.00 |
DisclosureSEC source: 0001209191-21-064866 · doc4.xml · derivative · entry 1 Khan Ruhi Ahmad · CIK 0001891113 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,000 Underlying: Common Stock · 225,000 shares Expires 2031-11-14 F1 · derivative.exercise_date: 25% of the shares subject to the option shall vest on November 8, 2022, and the remaining shares subject to the option shall vest monthly thereafter (1/48 of the shares per month for the 36 months following the one-year cliff), subject to the reporting person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.